Overview

NCI Definition: A rare, aggressive, poorly differentiated, non-small cell lung carcinoma characterized by the presence of a sarcomatoid component often associated with giant cell differentiation. There is a male to female ratio of 4:1. Clinical symptoms include cough, hemoptysis, chest pain, progressive dyspnea and fever secondary to recurrent pneumonia. Cigarette smoking is a major risk factor. [1]

Lung sarcomatoid carcinomas most frequently harbor alterations in TP53, KRAS, CDKN2A, MET, and CDKN2B [2].

Most Commonly Altered Genes in Lung Sarcomatoid Carcinoma

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in lung sarcomatoid carcinoma [2].

Top Alterations in Lung Sarcomatoid Carcinoma

Disease Details

Synonyms
sarcomatoid lung carcinoma
Parent(s)
Sarcomatoid Carcinoma
Children
Lung Spindle Cell Carcinoma, Lung Pleomorphic Carcinoma, and Lung Giant Cell Carcinoma
OncoTree Name
Sarcomatoid Carcinoma of the Lung
OncoTree Code
SARCL

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.